share_log

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

Benzinga ·  May 7 13:57

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment